港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

879.329

+3.4140.39%

漲家數：7

跌家數：8

平家數：2

市盈率：- -

高：885.329

開：878.139

低：871.523

收：875.916

成交量：1.24億

成交額：8.65億

市值：5,944.10億

流通市值：4,920.74億

資料載入中...

總覽新聞資訊

中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市

君實生物：公司將於9月14日召開2026年半年度業績説明會

证券日报网

上交所宣佈調整滬港通下港股通標的，調入百度、歌禮制藥等54只，調出佑駕創新等15只。

復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股

復星醫藥：復星高科技質押3.30億股用於償還債務

南方财经网

交銀國際：創新持續驅動醫藥高增長承壓板塊邊際改善盈利預期更趨樂觀

同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37

阿斯达克财经

大行評級丨星展：上調比亞迪電子目標價至40港元，維持「買入」評級

港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作

連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息

中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准

阿斯达克财经

【券商聚焦】交銀國際：醫藥行業收入穩健增長多重利好推動盈利表現顯著改善

勁方醫藥-B(02595)存倉市值總計19.55億港元股東將4373.09萬股股票存入渣打銀行(香港)

醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？

白雲山：2026年半年度權益分派實施公告

证券日报网

九州通與京東健康簽署戰略合作協議

南方财经网

王磊增持華潤萬象生活(01209)5萬股每股作價38.52港元

勁方醫藥-B(02595)9月3日斥資54.64萬港元回購2萬股

白雲山：每股派0.30元，股權登記日為9月9日

南方财经网

貝萊德在國藥控股的H股好倉比例下降0.18%至8.93%

南方财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1515/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":879.3294,"timestamp":1789537178521,"preClose":875.9157,"halted":0,"volume":124125793,"delay":0,"changeRate":0.003897,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":3.413696,"latestTime":"09-16 13:39:39","open":878.13885,"high":885.32947,"low":871.5229,"amount":865200082,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789546200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":1.316272,"peRate":17.057675,"turnoverRate":0.001699,"increases":7,"decrements":8,"flats":2,"marketCap":594410289984,"floatMarketCap":492074076032},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":885.32947,"amplitude":0.015762,"preClose":875.9157,"low":871.5229,"pbRate":"1.316272","latestPrice":879.3294,"volume":124125793,"delay":0,"open":878.13885,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":912.778,"twentyDayClose":905.419,"sixtyDayClose":815.098,"secType":"PLATE","market":"HK","turnoverRate":0.001699,"peRate":17.057675,"marketCap":594410289984,"floatMarketCap":492074076032,"timestamp":1789537178521,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":7,"down":8,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664334496","title":"中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00570","IPOS","06978","159992","BK1574","BK1515","IBBQ","BK1606","BK1161","MEDX","BK1191","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733252","title":"君實生物：公司將於9月14日召開2026年半年度業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733252","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664733252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:32","pubTimestamp":1788525120,"startTime":"0","endTime":"0","summary":"证券日报网讯9月4日，君实生物发布公告称，公司计划于2026年9月14日10：00-11：00举行2026年半年度业绩说明会。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqskus1210060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664233915","title":"上交所宣佈調整滬港通下港股通標的，調入百度、歌禮制藥等54只，調出佑駕創新等15只。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664233915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664233915?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 19:33","pubTimestamp":1788521612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000306701.USD","LU0307460666.USD","LU1831875114.USD","LU0164880469.USD","LU0543330566.HKD","02431","LU0359202008.SGD","LU1328615791.USD","89888","LU1481107354.HKD","HK0000306685.HKD","LU0244354667.USD","LU0823426308.USD","LU0463099449.HKD","LU0039217434.USD","BK1095","IE00B3M56506.USD","LU0856984785.SGD","LU0531971595.HKD","BIDU","LU0417516902.SGD","LU0287142896.SGD","LU0831093199.SGD","LU0326950275.SGD","BK1575","HK0000320264.USD","09888","BK1615","LU0819121731.USD","LU0072462343.USD","TCHI","LU0821914370.USD","01672","LU0359201612.USD","LU0640798160.USD","SG9999002828.SGD","LU1048588211.SGD","LU0197773673.USD","LU0043850808.USD","LU0051755006.USD","LU0762541174.USD","LU0359201885.HKD","LU0163747925.USD","SG9999002463.SGD","LU0228367735.SGD","LU0630378692.HKD","LU2039709279.SGD","LU0762540952.USD","LU0762542818.HKD","LU0315179316.USD","LU0871576103.HKD","LU1048596156.SGD","LU0588546209.SGD","LU0417516738.SGD","LU0149721374.USD","BK1144","BK1609","LU0823426480.USD","LU0348825331.USD","LU0173614495.USD","BK1515","LU0197773160.USD","LU0708995583.HKD","HK0000320223.HKD","LU1115378108.SGD","LU0630378429.USD","IE0034224299.USD","SG9999014674.SGD","LU0229945570.USD","LU2476274308.USD","LU0348735423.USD","LU1023057109.AUD","BK1574","LU0456827905.SGD","LU2778985437.USD","LU1188198961.HKD","LU0164865239.USD","BK1587","BK1588","LU0320764599.SGD","LU0052750758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338732","title":"復星醫藥(02196.HK)獲控股股東復星高科技質押3.3億股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 17:26","pubTimestamp":1788513984,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03188","02196","02827","07233","BK1515","BK1191","02846","03130","82846","83188","BK1147","83130","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840380","title":"復星醫藥：復星高科技質押3.30億股用於償還債務","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840380","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664840380?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:25","pubTimestamp":1788510357,"startTime":"0","endTime":"0","summary":"南财智讯9月4日电，复星医药公告，公司控股股东上海复星高科技(集团)有限公司于2026年9月3日将其持有的330000000股A股股份办理质押，占其所持股份比例34.32%，占公司总股本比例12.36%，质押用途为偿还债务。本次质押后，复星高科技累计质押股份数量为696275000股，占公司总股本26.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865437383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0028","BK0183","BK0188","BK0012","BK0175","BK0096","BK1593","BK0060","BK1191","600196","BK1515","BK0196","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382826","title":"交銀國際：創新持續驅動醫藥高增長 承壓板塊邊際改善 盈利預期更趨樂觀","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664382826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:50","pubTimestamp":1788504630,"startTime":"0","endTime":"0","summary":"创新药产业链增速领跑行业，服务板块复苏在各子板块中，创新产业链继续领跑行业：1)港股/A 股CXO 收入整体增长29.2%/25.3%，(扣非)净利润增长23.4%/67.6%，在各子板块中增速领先，汇率波动对表观利润率有一定压力，但行业整体景气度和订单需求处于高位。其中生物药增速远超化药，在板块收入中的占比也进一步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","BK1515","09939","03329","BK1574","ZECP","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381726","title":"同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381726","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381726?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:05","pubTimestamp":1788501900,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在下午02:05比前收市价上升5.029%，现股价为港币$6.37。至目前为止，今日最高价为$6.37，而最低价为$6.065。总成交量为410.589万股，总成交金额为港币$2.551千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1515","159938","BK1161","BK1574","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664038995","title":"大行評級丨星展：上調比亞迪電子目標價至40港元，維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664038995","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664038995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 13:14","pubTimestamp":1788498884,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1149","BK1540","BK1167","LU0348767384.USD","BK1607","BK1515","LU0274383008.USD","BK1504","BK1582","BK1580","00285","BK1589","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386607","title":"港股異動 | 四環醫藥(00460)午前漲近4% 軒竹生物與INNOBIC就吡洛西利於泰國市場達成商業化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386607?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","KCAI","BK1600","VXUS","BK1593","BK4588","02575","00460","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664138500","title":"連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138500","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138500?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:34","pubTimestamp":1788492846,"startTime":"0","endTime":"0","summary":"中国经济网北京9月4日讯 迪哲医药 昨日晚间发布关于董事、高级管理人员减持股份计划公告。　　迪哲医药称，上述减持对象本次减持数量占其本人本次减持前所持有公司股份数量均不超过25%。　　截至减持股份计划预披露公告发布前最后一个交易日，即2026年9月3日，迪哲医药收报60.08元，以此计算，上述减持主体本次减持金额合计预计为2.17亿元。　　经计算，迪哲医药上述两次募集资金金额合计为38.99亿元。　　迪哲医药自上市以来未分红。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260904/32360003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","03188","02827","399300","VIG","83188","02846","BK1161","83130","BK4588","159982","09939","07233","159938","82846","BK1147","03130","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664241388","title":"中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664241388","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664241388?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:24","pubTimestamp":1788485040,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团附属公司正大天晴自主研发的国家1类新药TQB6426“GPC3抗体药物偶联物(ADC)”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批准，拟用于晚期恶性肿瘤。目前，全球尚无靶向GPC3的ADC药物获批上市，同类候选产品整体处于临床前及早期临床探索阶段。集团将加速TQB6426的I期临床试验，评估其在晚期恶性肿瘤患者中的安全性、耐受性、药代动力学特征及初步疗效，尽早为全球肝细胞癌及更多实体瘤患者提供新的治疗选择。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-03 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1515","BK1589","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01477","01177","HK0000165453.HKD","BK1521","BK1191","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交銀國際：醫藥行業收入穩健增長 多重利好推動盈利表現顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664238859?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","HK0000306685.HKD","06821","01952","LU0307460666.USD","02596","LU1242518857.USD","02273","01177","01951","LU1152091168.USD","06160","01276","BK1589","01801","LU0327786744.USD","LU0856984785.SGD","BK1209","03692","02268","02096","KURE","BK1161","LU0039217434.USD","SG9999004220.SGD","LU2543165471.USD","IE00B543WZ88.USD","09926","03329","LU0348783233.USD","06996","06078","01093","03759","LU0315179316.USD","09966","HK0000320264.USD","06990","LU1880383366.USD","02269","IE00B5MMRT66.SGD","LU0588546209.SGD","BK1515","09996","01530","00013","02162","01548","KCE","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388377","title":"勁方醫藥-B(02595)存倉市值總計19.55億港元 股東將4373.09萬股股票存入渣打銀行(香港)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388377?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 08:34","pubTimestamp":1788482051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，劲方医药-B(02595)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。该公司股东将4373.09万股股票存入渣打银行(香港)，持股比例增加12.44%。劲方医药此前发布公告，GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌(NSCLC)的II期研究，包括单药疗法、联合EGFR单抗(西妥昔单抗)或联合化疗(培美曲塞)三种治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","159938","02595","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803502","title":"醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803502","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803502?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 23:41","pubTimestamp":1788450086,"startTime":"0","endTime":"0","summary":"02 8年磨一剑，基药目录送来“及时雨”恰在此时，基药目录更新了。二是基药目录首次纳入创新药。集采中标、医保谈判、基药目录入围构成了药品放量的三大政策通道。白马认为，基药目录的“及时雨”能解药企一时之渴，却解不了长期之渴。当医药代表退场的尘埃落定，当“带金销售”彻底成为过去式，真正能笑到最后的，是那些产品过硬、证据扎实、推广合规的药企。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788329362059116704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159938","09939","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083968","title":"白雲山：2026年半年度權益分派實施公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083968","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083968?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:32","pubTimestamp":1788442320,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月3日，白云山发布2026年半年度权益分派实施公告称，本次利润分配以方案实施前的公司总股本1，625，790，949股为基数，每股派发现金红利0.30元（含税），共计派发现金红利487，737，284.70元（含税）。股权登记日为2026年9月9日，除权（息）日为2026年9月10日。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-03/doc-iniqqfvs6793255.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-03/doc-iniqqfvs6793255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0175","BK0196","BK0188","BK1515","BK0070","BK0012","BK1197","BK0028","00874","BK0097","BK1191","BK1521","BK1606","BK0096","BK0239","BK0183","600332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874372","title":"九州通與京東健康簽署戰略合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874372","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874372?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:09","pubTimestamp":1788437340,"startTime":"0","endTime":"0","summary":"南方财经9月3日电，据九州通医药集团消息，9月3日，九州通医药集团（简称“九州通”）与京东健康签署战略合作协议。双方将共同整合渠道、供应链、技术与金融服务等领域的核心优势，围绕供应链、履约、消费场景与数智化采购等场景进行多维度深化协同，不断探索新模式、优化产业链效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864255516.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864255516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SGXZ62798434.SGD","BK1142","86618","BK1591","BK1571","BK0183","BK1515","BK1589","BK0077","BK0188","BK0039","BK0028","BK0201","BK0196","BK0250","BK1583","BK0012","BK0187","600998","LU0051755006.USD","BK0097","BK0146","06618","BK1247","LU0456827905.SGD","SGXZ86797644.SGD","BK1615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787979","title":"王磊增持華潤萬象生活(01209)5萬股 每股作價38.52港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787979","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787979?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435038,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月1日，王磊增持华润万象生活(01209)5万股，每股作价38.52港元，总金额为192.6万港元。增持后最新持股数目约为5万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01209","BK1501","BK1142","BK1542","BK1591","LU0082770016.USD","BK1571","BK1610","00241","LU0082770016.SGD","BK1584","LU0164939612.USD","BK1515","BK1589","HK0000165453.HKD","BK1189","BK1502","LU0456846285.SGD","BK1229","LU0620787316.HKD","BK1258","EWH","BK1583","LU0051755006.USD","BK1247","LU0456827905.SGD","BK1617","BK1615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879974","title":"勁方醫藥-B(02595)9月3日斥資54.64萬港元回購2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879974","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664879974?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:21","pubTimestamp":1788434461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月3日斥资54.64万港元回购2万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","09939","BK1574","159938","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875081","title":"白雲山：每股派0.30元，股權登記日為9月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875081","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875081?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:15","pubTimestamp":1788430500,"startTime":"0","endTime":"0","summary":"南财智讯9月3日电，白云山发布2026年半年度权益分派实施公告，每股派0.30元（含税），股权登记日为9月9日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864171782.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864171782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0175","BK0239","BK1191","BK1606","BK0188","BK1197","00874","BK0028","BK0070","BK0096","BK0183","BK0012","BK0196","600332","BK1521","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878268","title":"貝萊德在國藥控股的H股好倉比例下降0.18%至8.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878268","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878268?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 17:24","pubTimestamp":1788427440,"startTime":"0","endTime":"0","summary":"南财智讯9月3日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于8月31日从9.11%下降至8.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864136039.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864136039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1115378108.SGD","01099","BK1197","LU0640798160.USD","BK1515","BK1500"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":202,"code":"91000000","status":"200"}]}}